<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: The aim of this study was to assess the in vivo flow-metabolic phenotype in primary <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> with integrated (18)F-FDG PET/perfusion CT and its relationship to gold standard histopathologic assessment of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and <z:mp ids='MP_0005039'>hypoxia</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: 45 patients (26 male and 19 female; mean age, 67.6 y) with primary <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> underwent integrated (18)F-FDG PET/perfusion CT, deriving <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism (maximum standardized uptake value) and regional blood flow </plain></SENT>
<SENT sid="2" pm="."><plain>From this cohort, 35 underwent surgery subsequently, without intervening neoadjuvant treatment, allowing histopathologic correlation with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage, CD105 microvessel density, vascular endothelial growth factor (VEGF), <z:chebi fb="105" ids="17234">glucose</z:chebi> transporter protein 1 (Glut-1), and <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor 1 expression </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The flow-metabolic ratio was significantly lower for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with higher VEGF (3.65 vs. 5.98; P = 0.01) or <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor 1 expression (3.63 vs. 5.48; P = 0.04) versus <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with lower expression </plain></SENT>
<SENT sid="4" pm="."><plain>There were significant negative correlations between the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> flow-metabolic ratio and VEGF expression (r = -0.55, P = 0.0008), indicating that <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with low blood flow but higher metabolism were associated with higher VEGF expression </plain></SENT>
<SENT sid="5" pm="."><plain>Flow and metabolism were coupled in higher-stage (stage III/IV) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> but not lower-stage <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (stage I/II) (r = 0.47, P = 0.03, vs. r = 0.09, P = 0.65, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumors</z:e> with a low-flow-high-metabolism phenotype demonstrated higher VEGF expression and may reflect a more angiogenic phenotype </plain></SENT>
</text></document>